Welcome to the A16Z podcast. Today, we're having another of our hallway style conversations.

These episodes are based on videos that are also available on our YouTube channel.

YouTube.com slash C slash A16Z videos.

What's the path to success in the world of healthcare startups?

Bioteam general partners Jorge Condé and VJ Pandi discuss how founders

to adjust their plans for bringing a new

drug process, et cetera, to market. And how go-to-market models and players involved may differ

depending on the product, be it a molecule process or platform. Hey, we got VJ Pondi and Jorge Condi

here at General Partners at Andresen Horrods on the biofund. So we got lightning around today.

So we're seeing all these forces of biology coming to computer science and computer

science coming into biology.

You know, what's the lay a land of that?

Well, I think, I mean, this is a, as we all know, health care is a very complicated

landscape.

So let's just take it at a very high level. and then we can sort of dive in and go through sort of the various players here.

So if you're developing anything in the healthcare space, and let's just focus on human healthcare for a second to put a scope on this, generally speaking, if you're going to develop

a technology or a tool, you're going to develop something that's going to enable a drug

or a therapy, or you're going to enable something

that's going to enable the diagnostic to help detect disease. I mean, at a very high level,

it's tools, therapies, and diagnostic. So let's assume that you're playing in that space.

And you're thinking quite generally, the therapy could be many different types of therapies.

I guess we'll see. That's right. No, it could be, it could be a chemical. It could be a protein. It could be a cell.

...